A 6-month longitudinal study on worsening of parkinson’s disease during the covid-19 pandemic

ABSTRACT Further studies are required to investigate the impact of the COVID-19 pandemic on Parkinson’s disease (PD) progression. This study investigated the motor and non-motor progression

of people with PD (PWP) at 6 months during the COVID-19 pandemic compared with that during the pre-pandemic period. Patients were recruited from Ain Shams University Hospitals, Cairo, in the

period between April 2019 and December 2020. Fifty patients were included, of whom 17 and 33 patients were followed for 6 months before and during the pandemic, respectively. All patients

were assessed at baseline and at 6 months using the MDS-UPDRS, Schwab and England scale (S&E), Hoehn and Yahr scale (H&Y), Berg Balance Scale, Timed Up and Go test (TUG),

International Physical Activity Questionnaire, New Freezing of Gait Questionnaire, Non-Motor Symptoms Scale, and Beck Depression Inventory (BDI). Both groups were matched in age, gender, and

disease characteristics. Patients followed during the pandemic showed more significant worsening of the total, part I and motor part of MDS-UPDRS, and balance scores (_p_ < 0.001) than

those followed during the pre-COVID-19 period. Gait (TUG), balance, and physical activity worsening were significantly correlated with baseline BDI, gait and balance scores, total and part I

MDS-UPDRS scores, H&Y, and S&E OFF scores. Gait deterioration (TUG) was correlated with baseline physical activity (_r_ = −0.510, _p_ = 0.002). PWP showed worsening of motor and

non-motor symptoms during the COVID-19 pandemic at the 6-month follow-up. Worsening of gait, balance, and physical activity was correlated with baseline motor and physical activity OFF

scores. SIMILAR CONTENT BEING VIEWED BY OTHERS THE SEVERITY PROGRESSION OF NON-MOTOR SYMPTOMS IN PARKINSON’S DISEASE: A 6-YEAR LONGITUDINAL STUDY IN TAIWANESE PATIENTS Article Open access 20

July 2021 LONGITUDINAL EVOLUTION OF NON-MOTOR SYMPTOMS IN EARLY PARKINSON’S DISEASE: A 3-YEAR PROSPECTIVE COHORT STUDY Article Open access 15 July 2021 EARLY IDENTIFICATION OF SUBJECTIVE

COGNITIVE FUNCTIONAL DECLINE AMONG PATIENTS WITH PARKINSON’S DISEASE: A LONGITUDINAL PILOT STUDY Article Open access 23 December 2022 INTRODUCTION Since the outbreak of the coronavirus

disease 2019 (COVID-19) pandemic, individuals with Parkinson’s disease (PD) have been considered a vulnerable group to the effects of the COVID-19 pandemic, directly by infections with

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and indirectly by pandemic-related restrictions, chronic stress, anxiety, physical inactivity, and compromised medical care.

These effects included worsening of motor symptoms, higher mortality in advanced PD, worse anxiety and depression, impaired physical activity, and disruption of patients’ care1,2,3. Several

recent studies have linked reduced physical activity and exercise to motor worsening during the pandemic, implying the significance of maintaining patients’ activity during restrictions4,5.

Moreover, it has been proposed that the COVID-19 pandemic may be followed by a higher incidence of neurodegenerative diseases; however, the evidence is insufficient to confirm that COVID-19

may trigger or accelerate neurodegeneration6. However, the impact of the COVID-19 pandemic and related measures on disease progression has not been explored. A recent retrospective study has

reported a worsening of motor symptoms with a significant increase in motor disease progression during pandemic-related restrictions compared with that during the pre-pandemic period. The

assessment was limited to ON-state and motor aspects7. Therefore, longitudinal studies are warranted to investigate the possibility of altered progression of motor and non-motor aspects of

PD during the pandemic. Accordingly, the current longitudinal study investigated the short-term motor and non-motor progression and related determinants of a cohort of people with PD (PWP)

during the COVID-19 pandemic compared with the progression during the pre-pandemic period of another matched cohort. RESULTS Fifty patients were included, of whom 17 and 33 patients were

followed for 6 months before and during the pandemic, respectively. Both groups were matched for demographic and clinical characteristics except for longer disease duration (_p_ = 0.007) and

lower rigidity ON scores (_p_ = 0.01) for patients followed during the pandemic (Table 1). Physical activity ((International Physical Activity Questionnaire [IPAQ]) was non-significantly

lower in patients during the pandemic. All patients did not report symptoms suggestive of COVID-19 infection. Cronbach’s alpha coefficient of the questionnaires ranged from 0.75 to 0.98,

indicating a satisfactory internal consistency. DISEASE PROGRESSION BEFORE AND DURING THE COVID-19 PANDEMIC Patients followed before the pandemic showed a moderately significant progression

at 6 months of MDS-UPDRS-I (Non-Motor Aspects of Experiences of Daily Living [nM-EDL]) (_p_ = 0.044) and OFF-state motor scores (_p_ = 0.047). The Schwab and England Activities of Daily

Living scale (S&E) OFF- and ON-state scores showed a significant progression (_p_ = 0.04 and 0.011, respectively) although not H&Y. Postural Instability and Gait Disorder (PIGD) ON

and OFF-states, axial OFF-state, and New Freezing of Gait Questionnaire (NFOG-Q) OFF-state scores showed a moderately significant progression. The total non-motor symptoms scale (NMSS) and

IPAQ showed significant worsening (_p_ < 0.001) (Supplementary Table 1). The corrected _p_-value showed no significant changes, except for NMSS and IPAQ scores. Patients followed during

the COVID-19 pandemic showed a significant marked worsening at 6 months of MDS-UPDRS total and all subscores, S&E and Hoehn and Yahr (H&Y) (_p_ < 0.001), PIGD, NFOG-Q, Timed Up

and Go test (TUG), Berg Balance Scale (BBS) in OFF and ON states, total NMSS, IPAQ, and Mini-Mental State Examination (MMSE) (_p_ < 0.001) (Supplementary Table 2). Compared with the

patients followed before the pandemic, those followed during the pandemic had greater significant worsening of the total and motor MDS-UPDRS OFF- and ON-state scores, MDS-UPDRS part I (_p_ 

< 0.001), rigidity OFF (_p_ = 0.04) and ON-state scores (_p_ < 0.001), bradykinesia ON-state scores (_p_ < 0.001), BBS OFF- and ON-state scores (_p_ < 0.001) (significant after

Bonferroni correction), axial OFF-state scores, and TUG (_p_ = 0.01, non-significant after Bonferroni correction). Levodopa equivalent daily dosage (LEDD), MMSE, NMSS, IPAQ, and PDQ showed

similar changes in both groups (Table 2). CORRELATIONS OF DISEASE PROGRESSION DURING THE PANDEMIC During the pandemic, the worsening of motor severity (H&Y) was correlated with disease

duration (_r_ = 0.500, _p_ = 0.003), whereas motor complications (part IV) were directly correlated with baseline cognition (_p_ = 0.02) and S&E (_p_ = 0.03) and inversely correlated

with depression and total and motor MDS-UPDRS scores (_p_ = 0.04) (non-significant after Bonferroni correction); conversely, total and other MDS-UPDRS progression did not show significant

correlations (Table 3). Cognitive worsening was correlated with years of education, baseline MDS-UPDRS part II (_r_ = −0.430, _p_ = 0.01), PIGD (_r_ = −0.370, _p_ = 0.03), and axial scores

(_r_ = −0.370, _p_ = 0.03). Total NMSS worsening was correlated with baseline NFOG-Q (_r_ = 0.450, _p_ = 0.01) and PIGD scores (_r_ = 0.360, _p_ = 0.04) (non-significant after Bonferroni

correction). TUG (OFF), BBS (OFF), and IPAQ worsening were significantly correlated with baseline Beck Depression Inventory (BDI), gait (TUG) and balance (BBS) OFF scores, total and part I

MDS-UPDRS scores, and H&Y and S&E scores. After Bonferroni correction, a significant correlation was noted between TUG and baseline OFF-state TUG, PIGD, axial, H&Y, S&E, and

IPAQ scores; BBS and baseline OFF PIGD and NFOG-Q; and IPAQ and baseline MMSE, MDS-UPDRS-total and part II-OFF, BDI, TUG-OFF, and IPAQ scores (_p_ ≤ 0.002) (Table 3). On comparison between

the two groups regarding the assessment scale scores after 6 months, significant worsening was noted in MDS-UPDRS-I in the patients followed during the COVID-19 period (_p_ = 0.003)

(Supplementary Table 3). DISCUSSION Several cross-sectional studies have constantly described the worsening of motor and non-motor symptoms during the COVID-19 pandemic. However, its impact

on disease progression was not adequately investigated. Distinctively, this longitudinal study explored disease progression during the pandemic and showed worsening of motor and non-motor

symptoms over a 6-month follow-up during the pandemic compared with that during the pre-pandemic period. Gait, balance, and physical activity worsening were correlated with baseline motor

and physical activity scores. The current study showed the possibility of deleterious effects of pandemic lockdown on disease progression in PWP. The current findings are consistent with

those of previous cross-sectional studies. An Indian study showed worsening of motor symptoms, especially bradykinesia in 69.2% of cases during the COVID-19 pandemic, followed by tremor,

rigidity, and gait freezing8. Additionally, PWP reported worsening in mental health, quality of life, and physical inactivity during this pandemic5. These indirect effects of COVID-19 are

more confirmed and may be more common and more harmful than the direct effects of viral infections1,9,10. The worsening of motor and non-motor symptoms has been attributed to stress,

physical inactivity, pharmacodynamic effects, dramatic changes in routine, and social isolation11,12. The impact of stress on PD progression has been previously investigated and proven to

negatively affect the course of the disease1,2,4. Conversely, the impact on disease progression is not well investigated. However, a recent study by Ineichen et al. has reported increased

motor disease progression during pandemic-related restrictions compared with that before the COVID-19 pandemic, which is consistent with the current study7. Similar to symptom worsening,

more deterioration during the pandemic could be explained by stress, physical inactivity, and social isolation. PWP are more vulnerable to recent stressors, which is attributed to more

dopamine depletion and consequently reduced coping mechanisms for stress13. Moreover, chronic stress may induce oxidative damage to the cell membrane, as well as inflammatory and regulatory

T-cell dysfunction, leading to a possible increase in midbrain dopaminergic neuron loss and motor symptom worsening14. Additionally, chronic stress accelerates dopaminergic cell loss in

animal PD models and exacerbates the neuropathological changes15. The accompanying microglial activation and oxidative stress may mechanistically justify the stress-induced neurodegeneration

in PD16. Remarkably, gait (TUG), balance, and physical activity were markedly worsened during the pandemic, which was related to baseline motor and physical activity scores. Consistently, a

recent study, which assessed 12 patients before and 2 months after lockdown, has shown moderate gait, falls, and balance worsening although not freezing of gait, despite being contacted by

a multidisciplinary team17. Approximately 29% of patients with PD are less physically active than the normal population, which are predicated by disease severity, gait, and impairment of

activities of daily living18. Increased physical activity and exercise have a positive effect on motor and non-motor symptoms and probably PD disease progression19. Moreover, exercise may

improve the progression of PD manifestations and enhance motor and cognitive circuit-related neuroplasticity20,21,22. Despite there being no reported cases of SARS-CoV-2 infection, its

direct effect on disease progression due to subclinical infection could not be totally excluded. An Italian study reported motor and non-motor deterioration that was attributed to infection

and drug pharmacodynamic-related mechanisms. A quarter of patients with PD and COVID-19 had mild symptoms and recovered without treatment23. SARS-CoV-2-related neurodegenerations, especially

nigrostriatal degenerations, have been proposed owing to the possibility of neuro-invasion via the olfactory bulb, Angiotensin-Converting Enzyme 2 (ACE2) receptor expression by dopaminergic

neurons, associated inflammatory and vascular changes that overlap with PD pathogenesis, and progression in addition to reported cases of SARS-CoV-2-related parkinsonism with dopamine

transporter imaging abnormalities1,24. However, the impact of COVID-19 on neurodegeneration, including the development or increased progression of PD, has not yet been confirmed. The

strengths of the current study include the comprehensive assessment in the OFF and ON states and follow-up of patients with mild-to-moderate PD before and during the pandemic, with a

comprehensive assessment of motor and non-motor symptoms and matched baseline characteristics of patients in both groups. The current study has some limitations. The small number and short

follow-up period, as well as the lack of confirmation or exclusion of SARS-CoV-2 infection using laboratory tests during assessments, are considered its limitations. Furthermore, our cohort

included patients with mild-to-moderate PD who should be considered in the interpretation of our findings. This study confirms the impact of the COVID-19 pandemic on the motor and non-motor

symptoms of PD and demonstrates another possible effect, which is the short-term worsening of disease progression, implying the significance of managing related factors, including anxiety,

chronic stress, and physical inactivity, and considering this effect in interpreting longitudinal studies during the pandemic. METHODS This is a retrospective analysis of the data from our

longitudinal study (PDPRO-EGY, clinicalTrial.gov, NCT04062279) that investigated the progression of Egyptian patients with PD. Patients were recruited from the movement disorders outpatient

clinic of Ain Shams University Hospitals (Cairo, Egypt) in the period between April 2019 and December 2020. Patients with PD who were diagnosed using the International Parkinson and Movement

Disorders Society (MDS) diagnostic criteria25 and completed both baseline and 6-month follow-up assessments before or during the pandemic period were included and compared. Patients who

completed baseline and follow-up assessments during the pandemic were included as the “one group” (from March to December 2020), whereas those who completed the follow-up before March 2020

(before lockdown procedures in Egypt) were included as the “control group.” Patients excluded include patients with atypical or acquired parkinsonism, those who did not complete the

follow-up assessment, those who were assessed in the pre-pandemic (baseline) and during the pandemic (6-month follow-up) periods, and those who underwent functional brain surgery (before or

during the follow-up period). SAMPLING AND SAMPLE SIZE The sample size was calculated using an online calculator (https://www.calculator.net/sample-size-calculator.html), where for a 95%

confidence level and a margin of error 5, the minimal sample size was estimated to be 16 patients for each group. ETHICAL CONSIDERATIONS All participants provided written informed consent.

The study was approved by the ethical committee of the Faculty of Medicine of Ain Shams University according to the Declaration of Helsinki. DATA COLLECTION All patients were evaluated at

baseline and at 6-month follow-up using the total and different parts of the MDS-UPDRS (parts include part I [nM-EDL], part II [motor aspects of daily living], part III [motor examination],

and part IV [motor complications]), H&Y for disease severity, S&E for activities of daily living26, NFOG-Q27 for gait freezing, BBS28 for balance assessment, and TUG29 for gait and

mobility assessment during the OFF and ON states. Other scales included the IPAQ-SF30 for physical activities, NMSS31 for non-motor symptoms evaluation, Arabic version of BDI32 for

depression, Arabic version of PD questionnaire 3933 for quality of life, and MMSE34 for cognition. All patients have been evaluated in person by a trained physician. LEDD was calculated at

baseline and follow-up as the sum of the daily dose of all dopaminergic agents35. STATISTICAL ANALYSIS Data analysis was performed using IBM SPSS software package version 25.0 (IBM Corp.,

Armonk, NY). Qualitative data were described as frequencies and percentages and compared using the chi-square test, whereas quantitative data were presented as medians and interquartile

ranges or means ± standard deviations and compared using either the Mann–Whitney _U_ test or Student’s _t_ test according to the distribution of the data, respectively. The Wilcoxon

signed-rank test was used to compare baseline and follow-up data within each group. The Spearman correlation coefficient was used to evaluate the correlation between different variables. The

significance was set at _p_ < 0.05. Bonferroni correction was performed for the multiple comparisons and correlations, and an adjusted p-value was used. Cronbach’s α coefficient was used

as a measure of the internal consistency of used questionnaires. DATA AVAILABILITY The datasets generated during the current study will be made available from the corresponding author upon

request. REFERENCES * Fearon, C. & Fasano, A. Parkinson’s disease and the COVID-19 pandemic. _J. Parkinsons Dis._ 11, 431–444 (2021). Article  CAS  Google Scholar  * Helmich, R. C. &

Bloem, B. R. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. _J. Parkinsons Dis._ 10, 351–354 (2020). Article  CAS  Google Scholar  *

Feeney, M. P. et al. The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study. _npj Parkinsons Dis._ 7, 10 (2021). Article  CAS  Google Scholar  * van

der Heide, A., Meinders, M. J., Bloem, B. R. & Helmich, R. C. The impact of the COVID-19 pandemic on psychological distress, physical activity, and symptom severity in Parkinson’s

disease. _J. Parkinsons Dis._ 10, 1355–1364 (2020). Article  Google Scholar  * Shalash, A. et al. Mental health, physical activity, and quality of life in Parkinson’s disease during COVID-19

pandemic. _Mov. Disord._ 35, 1097–1099 (2020). Article  CAS  Google Scholar  * Krey, L., Huber, M. K., Hoglinger, G. U., Wegner, F. & Can, S.-C. Can SARS-CoV-2 Infection lead to

neurodegeneration and Parkinson’s disease? _Brain Sci._ 11, 1654 (2021). Article  CAS  Google Scholar  * Ineichen, C., Baumann-Vogel, H., Sitzler, M., Waldvogel, D. & Baumann, C. R.

Worsened Parkinson’s disease progression: impact of the COVID-19 pandemic. _J. Parkinsons Dis._ 11, 1579–1583 (2021). Article  CAS  Google Scholar  * Saluja, A., Parihar, J., Garg, D. &

Dhamija, R. K. The impact of COVID-19 pandemic on disease severity and quality of life in Parkinson’s disease. _Ann. Indian Acad. Neurol._ 24, 217–226 (2021). PubMed  PubMed Central  Google

Scholar  * Chaudhry, Z. L. et al. ER Stress in COVID-19 and Parkinson’s disease: in vitro and in silico evidences. _Brain Sci_. 12. https://doi.org/10.3390/brainsci12040507 (2022). *

Goerttler, T. et al. SARS-CoV-2, COVID-19 and Parkinson’s disease-many issues need to be clarified-A critical review. _Brain Sci_. 12. https://doi.org/10.3390/brainsci12040456 (2022). *

Vignatelli, L. et al. The indirect impact of COVID-19 on major clinical outcomes of people with Parkinson’s disease or Parkinsonism: a cohort study. _Front. Neurol._ 13, 873925 (2022).

Article  Google Scholar  * Hermanowicz, N. et al. Impact of isolation during the COVID-19 pandemic on the patient burden of Parkinson’s disease: a PMD alliance survey. _Neuropsychiatr. Dis.

Treat._ 18, 633–643 (2022). Article  Google Scholar  * Douma, E. H. & de Kloet, E. R. Stress-induced plast. functioning ventral tegmental dopamine neurons. _Neurosci. Biobehav. Rev._

108, 48–77 (2020). Article  CAS  Google Scholar  * Goldstein, D. S. Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases. _Cell Mol. Neurobiol._

32, 661–666 (2012). Article  CAS  Google Scholar  * Smith, L. K., Jadavji, N. M., Colwell, K. L., Katrina Perehudoff, S. & Metz, G. A. Stress accelerates neural degeneration and

exaggerates motor symptoms in a rat model of Parkinson’s disease. _Eur. J. Neurosci._ 27, 2133–2146 (2008). Article  Google Scholar  * Sugama, S. et al. Chronic restraint stress triggers

dopaminergic and noradrenergic neurodegeneration: possible role of chronic stress in the onset of Parkinson’s disease. _Brain Behav. Immun._ 51, 39–46 (2016). Article  CAS  Google Scholar  *

Luis-Martínez, R. et al. Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown. _BMC Neurol._ 21, 332 (2021). Article  Google Scholar  * van Nimwegen,

M. V. et al. Physical inactivity in Parkinson’s disease. _J. Neurol._ 258, 2214–2221 (2011). Article  Google Scholar  * Bouça‐Machado, R. et al. Physical activity, exercise, and

physiotherapy in Parkinson’s disease: defining the concepts. _Mov. Disord. Clin. Pract._ 7, 7–15 (2020). Article  Google Scholar  * Petzinger, G. M. et al. Exercise-enhanced neuroplasticity

targeting motor and cognitive circuitry in Parkinson’s disease. _Lancet Neurol._ 12, 716–726 (2013). Article  Google Scholar  * Paul, K. C. et al. The association between lifestyle factors

and Parkinson’s disease progression and mortality. _Mov. Disord._ 34, 58–66 (2019). Article  Google Scholar  * Amara, A. W. et al. Self-reported physical activity levels and clinical

progression in early Parkinson’s disease. _Parkinsonism Relat. Disord._ 61, 118–125 (2019). Article  Google Scholar  * Cilia, R. et al. Effects of COVID-19 on Parkinson’s disease clinical

features: a community-based case-control study. _Mov. Disord._ 35, 1287–1292 (2020). Article  CAS  Google Scholar  * Bouali-Benazzouz, R. & Benazzouz, A. Covid-19 infection and

Parkinsonism: is there a link? _Mov. Disord._ 36, 1737–1743 (2021). Article  CAS  Google Scholar  * Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. _Mov.

Disord._ 30, 1591–1601 (2015). Article  Google Scholar  * Goetz, C. G. et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale

presentation and clinimetric testing results. _Mov. Disord._ 23, 2129–2170 (2008). Article  Google Scholar  * Giladi, N. et al. Validation of the freezing of gait questionnaire in patients

with Parkinson’s disease. _Mov. Disord._ 24, 655–661 (2009). Article  Google Scholar  * Berg, K. O., Wood-Dauphinee, S. L., Williams, J. I. & Maki, B. Measuring balance in the elderly:

validation of an instrument. _Can. J. Public Health_ 83, S7–S11 (1992). PubMed  Google Scholar  * Bohannon, R. W. Reference values for the timed up and go test: a descriptive meta-analysis.

_J. Geriatr. Phys. Ther._ 29, 64–68 (2006). Article  Google Scholar  * Craig, C. L. et al. International physical activity questionnaire: 12-country reliability and validity. _Med. Sci.

Sports Exerc._ 35, 1381–1395 (2003). Article  Google Scholar  * Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an

international pilot study. _Mov. Disord._ 22, 1901–1911 (2007). Article  Google Scholar  * Fawzi, M. H., Fawzi, M. M. & Abu-Hindi, W. Arabic version of the Major Depression Inventory as

a diagnostic tool: reliability and concurrent and discriminant validity. _East. Mediterr. Health J. Arabic version_ 18, 304–310 (2012). Article  CAS  Google Scholar  * Shalash, A. S. et al.

Non-motor symptoms as predictors of quality of life in Egyptian patients with Parkinson’s disease: a cross-sectional study using a culturally adapted 39-Item Parkinson’s disease

questionnaire. _Front. Neurol._ 9, 357 (2018). Article  Google Scholar  * Tuijl, J. P., Scholte, E. M., de Craen, A. J. & van der Mast, R. C. Screening for cognitive impairment in older

general hospital patients: comparison of the six-Item Cognitive Impairment Test with the Mini-Mental State Examination. _Int. J. Geriatr. Psychiatry_ 27, 755–762 (2012). Article  Google

Scholar  * Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. _Mov. Disord._ 25, 2649–2653 (2010). Article  Google Scholar  Download

references FUNDING Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt Ali Shalash, Asmaa Helmy, Ahmed Gaber, Mahmoud El-Belkimy & Eman Hamid *

Institute of Global Health and Human Ecology (I-GHHE), the American University in Cairo, Cairo, Egypt Mohamed Salama * Faculty of Medicine, Mansoura University, Mansoura, Egypt Mohamed

Salama Authors * Ali Shalash View author publications You can also search for this author inPubMed Google Scholar * Asmaa Helmy View author publications You can also search for this author

inPubMed Google Scholar * Mohamed Salama View author publications You can also search for this author inPubMed Google Scholar * Ahmed Gaber View author publications You can also search for

this author inPubMed Google Scholar * Mahmoud El-Belkimy View author publications You can also search for this author inPubMed Google Scholar * Eman Hamid View author publications You can

also search for this author inPubMed Google Scholar CONTRIBUTIONS Research project: conception: A.S. and M.E., organization: A.S. and E.H., and execution: A.H., E.H., A.G., and A.S.;

statistical analysis: design and execution: E.H. and A.S., and review and critique: A.G., M.E., and M.S.; thematic analysis: design and execution: A.H., E.H., and A.S., and review and

critique: A.S., A.G., M.E., and M.S.; and manuscript: writing of the first draft: A.S., E.H.; and review and critique: A.S., E.H., A.G., M.E., and M.S. CORRESPONDING AUTHOR Correspondence to

Ali Shalash. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMNTARY TABLES RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a

Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are

included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and

your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this

license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Shalash, A., Helmy, A., Salama, M. _et al._ A 6-month longitudinal

study on worsening of Parkinson’s disease during the COVID-19 pandemic. _npj Parkinsons Dis._ 8, 111 (2022). https://doi.org/10.1038/s41531-022-00376-x Download citation * Received: 25

January 2022 * Accepted: 12 August 2022 * Published: 31 August 2022 * DOI: https://doi.org/10.1038/s41531-022-00376-x SHARE THIS ARTICLE Anyone you share the following link with will be able

to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative